Tenax Therapeutics gains after FDA clears hypertension drug application

Tenax Therapeutics

06/10/2021 14:44

** Shares of the pharmaceutical firm  TENX.O  are up 0.6% at
$1.82 
    ** Co says FDA has reviewed and cleared its IND application
for imatinib in pulmonary arterial hypertension (PAH)
 urn:newsml:reuters.com:*:nBw3RG1V5a
    ** "Imatinib has already been clinically proven to be
effective in pulmonary arterial hypertension (PAH), and with our
unique formulation, we anticipate a better tolerated, and thus
more effective, treatment option - CEO Christopher Giordano said
    ** Unique, delayed-release formulation of imatinib designed
to avoid gastric intolerance
    ** Co reformulated imatinib to specifically address the
gastric intolerance associated with its older, oral formulation
    ** Up to Tuesday's close, stock has lost 2.7% YTD

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))